NANOBIOTIX Completes Global Offering with $100 Million Proceeds

NANOBIOTIX, a late-clinical stage biotech company, announced the successful closing of its global offering, raising approximately $100 million. This includes the full exercise of underwriters' options, resulting in the issuance of 2,218,467 Ordinary Shares and pre-funded warrants.

The company plans to allocate 50-60% of the proceeds to advance its Nanoprimer platform, less than 10% for the development of JNJ-1900 (NBTXR3), and 30-40% for general corporate purposes. This financing is expected to support operations until 2029.

The securities were offered under a shelf registration statement filed with the SEC. Jefferies, TD Cowen, and Stifel were the global coordinators for the offering.